NLRP3 and colitis: Exogenous agents like a butyrate-melatonin complex can halt colitis progression by dual modulation of the microbiome and the NLRP3/caspase-1 pathway, effectively re-educating macrophages towards an anti-inflammatory phenotype [70,71,72].